Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


14 08, 2015

Understanding our future: immunotherapies

Tags: , , |2 Comments

I just listened to one of the best and easiest to understand videos I've found, explaining how the new monoclonal antibodies (elotuzumab and daratumumab) work. My good friend and long lived myeloma survivor, Jack Aiello, is interviewing Dana-Farber's Dr. Paul Richardson on a Patient Power broadcast. It's short and to the point. Give it a

3 06, 2015

ASCO News: 11;14 translocation data and elotuzumab results underwhelming

Tags: , , , , |2 Comments

I'm still hoping for some significant myeloma related data to emerge as the American Society of Clinical Oncology (ASCO) meetings wide down in Chicago.  In the meantime, the Myeloma Beacon did a nice job reviewing several poster studies which focused on my genetic abnormality: an 11;14 translocation I developed after my first stem cell transplant.

8 03, 2015

Experts discuss new drugs likely to be approved by FDA

Tags: , , |0 Comments posted a six member panel discussion about the two experimental drugs most likely to be approved next by the FDA: elotuzumab and ixazomib (MLN9708). The impressive group of panelists included doctors James R. Berenson, Sundar Jagannath, Shaji Kumar, Sagar Lonial, Keith K. Stewart and Jeffrey A. Zonder.  Here's a write-up about the exchange, along

23 02, 2015

Myeloma therapy advances big and small

Tags: , , , |12 Comments

Speaking of new treatment options, here's an excerpt from an excellent summary of what I consider to be "stopgap" myeloma therapy measures until new immunotherapy technology moves front and center: Treatment Triplets Offer New Strategies in Relapsed Multiple Myeloma Anita T. Shaffer - Published Online: Friday, February 20, 2015 The treatment options for patients

18 11, 2014

Early myeloma related ASH announcements

Tags: , , , , , |5 Comments

I've very excited!  Yesterday my registration materials arrived for next month's American Society of Hematology (ASH) annual meetings in San Francisco.  And like clockwork, researchers and pharmaceutical companies have started issuing press releases promoting presentations featuring clinical trial results to be presented there. Here are two early examples.  Keep in mind that a lot new

28 09, 2014

Which new myeloma drug will the FDA approve next?

Tags: , , , , |7 Comments

There are a half dozen experimental anti-myeloma drugs nearing the end of the research pipeline.  Which is most likely to be approved and when? A biologic immunotherapy drug like elotuzumab or daratumumab?  Millennium's new oral proteasome inhibitor, MLN9708? Although it only works well when combined with another drug like Revlimid, elotuzumab is the farthest along. 

27 04, 2014

Proof clarithromycin can help overcome myeloma drug resistance

Tags: , , , , |4 Comments

From what may be possible in the future to an easy way to temporarily overcome myeloma drug resistance now. Apparently adding something as simple and innocuous as an antibiotic can add four or more months of effectiveness to fading Revlimid therapy.  Here's the abstract from a study published Friday in the American Journal of Hematology,

21 10, 2013

New pathway may hold key to multiple myeloma cure

Tags: , , , , , |16 Comments

Could immunotherapy be the key to a multiple myeloma cure?  One thing's for sure; new drugs like elotuzumab and daratumumab offer hope that researchers are developing new and significant ways to attack our cancer. The International Myeloma Foundation's, Dr. Brian Durie, blogs about immunotherapy in this month's edition of the IMF's Myeloma Minute.  Here's an

14 09, 2013

Daratumumab ready for Stage 2 testing

Tags: , , , , |3 Comments

Always nice to report on a promising development.  Check-out this press release about the new rising myeloma therapy star, daratumumab, that I received last week: Genmab Announces New Study of Daratumumab in Double Refractory Myeloma Genmab Announces New Study of Daratumumab in Double Refractory Multiple Myeloma      -- After initial data read-out in Part

18 06, 2013

Missing in action at ASCO, ARRY-520 hot topic in Europe

Tags: , , , , , |9 Comments

Something was missing from this year's American Society of Clinical Oncology (ASCO) meetings in Chicago this year.  Conspicuously absent was any news about one of the most promising anti-myeloma drugs, ARRY-520.  Why?  Was there a problem with ARRY-520's trial data? Absolutely not!  It turns-out that decision makers at the company that is developing ARRY-520, Array

2 06, 2013

Elotuzumab study results “promisingly murky”

Tags: , , , , |12 Comments

For me, one of the most frustrating part of reading abstracts and following oral presentation myeloma results at meetings like ASCO and ASH is that you are rarely comparing apples to apples.  Are study subjects "heavily pretreated," "refractory," or both.  And what about "relapsed?"  Sometimes some of these terms are used interchangeably.  Sometimes not.  Let

26 05, 2013

Video interviews examine the emotional and scientific side of multiple myeloma

Tags: , , , , , , |0 Comments

New Andrew Schorr Patient Power video features an interview with experienced cancer care social worker, Brianna Garrison, at M.D. Anderson Cancer Center in Houston, Texas.  Brianna discusses how she helps patients cut-through the clutter and focus on what's important to them. Tying-in with Danny Parker's recent Excercise and Multiple Myeloma series, Brianna discusses ways to